BACKGROUND. The idiotypic determinants of the surface immunoglobulin of a B-cell lymphoma can serve as a clonal tumor-specific marker, which may have implications for immunotherapy. We sought to determine whether idiotype-specific immune responses against this autologous antigen could be induced in patients with B-cell lymphoma. METHODS. Nine patients were selected who had minimal residual disease or a complete remission after chemotherapy. Each received a series of subcutaneous injections of the immunoglobulin derived from his or her tumor cells (immunoglobulin-idiotype protein), which had been conjugated to a protein carrier and mixed with an immunologic adjuvant. RESULTS. In seven of the nine patients the injections induced sustained idiotype-specific immunologic responses of the humoral type (two patients), the cell-mediated type (four patients), or both (one patient). The use of an adjuvant was essential for these immune responses. The induced antibodies bound specifically to autologous immunoglobulin idiotype, inhibited the binding of murine monoclonal antiidiotype antibodies, and bound autologous tumor cells. Cell-mediated responses were demonstrated by the specific proliferation of immune peripheral-blood mononuclear cells to the soluble immunoglobulin-idiotype protein in vitro. The tumors of both of the patients with measurable disease regressed completely. Toxicity associated with the vaccine was minimal and consisted only of mild reactions at the site of intramuscular injection. CONCLUSIONS. These results demonstrate that autologous immunoglobulin idiotype can be formulated into an immunogenic, tumor-specific antigen in humans with B-cell lymphoma, and they provide the background for large-scale trials of active specific immunotherapy of this disease.
Source Information
Department of Medicine, Stanford University School of Medicine, Calif.
This article has been cited by other articles:
Betting, D. J., Kafi, K., Abdollahi-Fard, A., Hurvitz, S. A., Timmerman, J. M.
(2008). Sulfhydryl-Based Tumor Antigen-Carrier Protein Conjugates Stimulate Superior Antitumor Immunity against B Cell Lymphomas. J. Immunol.
181: 4131-4140
[Abstract][Full Text]
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinkski, D. K., Vojdani, F., Hanley, K. M., Garger, S. J., White, E. L., Novak, J., Barrett, J., Holtz, R. B., Tuse, D., Levy, R.
(2008). Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. Proc. Natl. Acad. Sci. USA
105: 10131-10136
[Abstract][Full Text]
Friedrichs, B., Siegel, S., Kloess, M., Barsoum, A., Coggin, J. Jr., Rohrer, J., Jakob, I., Tiemann, M., Heidorn, K., Schulte, C., Kabelitz, D., Steinmann, J., Schmitz, N., Zeis, M.
(2008). Humoral Immune Responses against the Immature Laminin Receptor Protein Show Prognostic Significance in Patients with Chronic Lymphocytic Leukemia. J. Immunol.
180: 6374-6384
[Abstract][Full Text]
Houot, R., Levy, R.
(2008). Therapeutic Vaccine for Lymphoma: Lessons Learned and Future Directions. aacredbook
2008: 3-11
[Full Text]
Franki, S. N., Steward, K. K., Betting, D. J., Kafi, K., Yamada, R. E., Timmerman, J. M.
(2008). Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood
111: 1504-1511
[Abstract][Full Text]
Chakraverty, R., Sykes, M.
(2007). The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood
110: 9-17
[Abstract][Full Text]
Neelapu, S. S., Gause, B. L., Harvey, L., Lee, S.-T., Frye, A. R., Horton, J., Robb, R. J., Popescu, M. C., Kwak, L. W.
(2007). A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood
109: 5160-5163
[Abstract][Full Text]
Popescu, M. C., Robb, R. J., Batenjany, M. M., Boni, L. T., Neville, M. E., Pennington, R. W., Neelapu, S. S., Kwak, L. W.
(2007). A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood
109: 5407-5410
[Abstract][Full Text]
Kanter, G., Yang, J., Voloshin, A., Levy, S., Swartz, J. R., Levy, R.
(2007). Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood
109: 3393-3399
[Abstract][Full Text]
Radcliffe, C. M., Arnold, J. N., Suter, D. M., Wormald, M. R., Harvey, D. J., Royle, L., Mimura, Y., Kimura, Y., Sim, R. B., Inoges, S., Rodriguez-Calvillo, M., Zabalegui, N., de Cerio, A. L.-D., Potter, K. N., Mockridge, C. I., Dwek, R. A., Bendandi, M., Rudd, P. M., Stevenson, F. K.
(2007). Human Follicular Lymphoma Cells Contain Oligomannose Glycans in the Antigen-binding Site of the B-cell Receptor. J. Biol. Chem.
282: 7405-7415
[Abstract][Full Text]
Weng, W.-K., Czerwinski, D., Levy, R.
(2007). Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood
109: 951-953
[Abstract][Full Text]
Neelapu, S. S., Kwak, L. W.
(2007). Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies. ASH Education Book
2007: 243-249
[Abstract][Full Text]
Zirlik, K. M., Zahrieh, D., Neuberg, D., Gribben, J. G.
(2006). Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood
108: 3865-3870
[Abstract][Full Text]
Longo, D. L.
(2006). Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.. JNCI J Natl Cancer Inst
98: 1263-1265
[Full Text]
Inoges, S., Rodriguez-Calvillo, M., Zabalegui, N., Lopez-Diaz de Cerio, A., Villanueva, H., Soria, E., Suarez, L., Rodriguez-Caballero, A., Pastor, F., Garcia-Munoz, R., Panizo, C., Perez-Calvo, J., Melero, I., Rocha, E., Orfao, A., Bendandi, M.
(2006). Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.. JNCI J Natl Cancer Inst
98: 1292-1301
[Abstract][Full Text]
Redfern, C. H., Guthrie, T. H., Bessudo, A., Densmore, J. J., Holman, P. R., Janakiraman, N., Leonard, J. P., Levy, R. L., Just, R. G., Smith, M. R., Rosenfelt, F. P., Wiernik, P. H., Carter, W. D., Gold, D. P., Melink, T. J., Gutheil, J. C., Bender, J. F.
(2006). Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses. JCO
24: 3107-3112
[Abstract][Full Text]
Bertinetti, C., Zirlik, K., Heining-Mikesch, K., Ihorst, G., Dierbach, H., Waller, C. F., Veelken, H.
(2006). Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.. Cancer Res.
66: 4496-4502
[Abstract][Full Text]
Maloney, D. G.
(2005). Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines. JCO
23: 6421-6428
[Abstract][Full Text]
Muraro, S., Bondanza, A., Bellone, M., Greenberg, P. D., Bonini, C.
(2005). Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. Blood
105: 3596-3604
[Abstract][Full Text]
Palomba, M. L., Roberts, W. K., Dao, T., Manukian, G., Guevara-Patino, J. A., Wolchok, J. D., Scheinberg, D. A., Houghton, A. N.
(2005). CD8+ T-Cell-Dependent Immunity Following Xenogeneic DNA Immunization against CD20 in a Tumor Challenge Model of B-Cell Lymphoma. Clin. Cancer Res.
11: 370-379
[Abstract][Full Text]
Neelapu, S. S., Baskar, S., Gause, B. L., Kobrin, C. B., Watson, T. M., Frye, A. R., Pennington, R., Harvey, L., Jaffe, E. S., Robb, R. J., Popescu, M. C., Kwak, L. W.
(2004). Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen. Clin. Cancer Res.
10: 8309-8317
[Abstract][Full Text]
Weng, W.-K., Czerwinski, D., Timmerman, J., Hsu, F. J., Levy, R.
(2004). Clinical Outcome of Lymphoma Patients After Idiotype Vaccination Is Correlated With Humoral Immune Response and Immunoglobulin G Fc Receptor Genotype. JCO
22: 4717-4724
[Abstract][Full Text]
Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., Miller, T. P., LeBlanc, M., Greiner, T. C., Weisenburger, D. D., Lynch, J. C., Vose, J., Armitage, J. O., Smeland, E. B., Kvaloy, S., Holte, H., Delabie, J., Connors, J. M., Lansdorp, P. M., Ouyang, Q., Lister, T. A., Davies, A. J., Norton, A. J., Muller-Hermelink, H. K., Ott, G., Campo, E., Montserrat, E., Wilson, W. H., Jaffe, E. S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M., Staudt, L. M.
(2004). Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. NEJM
351: 2159-2169
[Abstract][Full Text]
Zamvil, S. S., Prod'homme, T.
(2004). The APC's of tumor vaccine therapy. Blood
104: 1915-1916
[Full Text]
Lou, Q., Kelleher, R. J. Jr, Sette, A., Loyall, J., Southwood, S., Bankert, R. B., Bernstein, S. H.
(2004). Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells. Blood
104: 752-759
[Abstract][Full Text]
Mapara, M. Y., Sykes, M.
(2004). Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance. JCO
22: 1136-1151
[Abstract][Full Text]
Grube, M., Rezvani, K., Wiestner, A., Fujiwara, H., Sconocchia, G., Melenhorst, J. J., Hensel, N., Marti, G. E., Kwak, L. W., Wilson, W., Barrett, J. A.
(2004). Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies. Clin. Cancer Res.
10: 1047-1056
[Abstract][Full Text]
Milazzo, C., Reichardt, V. L., Muller, M. R., Grunebach, F., Brossart, P.
(2003). Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood
101: 977-982
[Abstract][Full Text]
Borson, N. D., Lacy, M. Q., Wettstein, P. J.
(2002). Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood
100: 4629-4639
[Abstract][Full Text]
Gatza, E., Okada, C. Y.
(2002). Tumor Cell Lysate-Pulsed Dendritic Cells Are More Effective Than TCR Id Protein Vaccines for Active Immunotherapy of T Cell Lymphoma. J. Immunol.
169: 5227-5235
[Abstract][Full Text]
Timmerman, J. M., Singh, G., Hermanson, G., Hobart, P., Czerwinski, D. K., Taidi, B., Rajapaksa, R., Caspar, C. B., van Beckhoven, A., Levy, R.
(2002). Immunogenicity of a Plasmid DNA Vaccine Encoding Chimeric Idiotype in Patients with B-Cell Lymphoma. Cancer Res.
62: 5845-5852
[Abstract][Full Text]
Espinoza-Delgado, I.
(2002). Cancer Vaccines. The Oncologist
7: 20-33
[Abstract][Full Text]
Hunault-Berger, M., Ifrah, N., Solal-Celigny, P.
(2002). Intensive therapies in follicular non-Hodgkin lymphomas. Blood
100: 1141-1152
[Full Text]
Krackhardt, A. M., Harig, S., Witzens, M., Broderick, R., Barrett, P., Gribben, J. G.
(2002). T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood
100: 167-173
[Abstract][Full Text]
Roberts, W. K., Livingston, P. O., Agus, D. B., Pinilla-Ibarz, J., Zelenetz, A., Scheinberg, D. A.
(2002). Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood
99: 3748-3755
[Abstract][Full Text]
Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B., Rajapaksa, R., Caspar, C. B., Okada, C. Y., van Beckhoven, A., Liles, T. M., Engleman, E. G., Levy, R.
(2002). Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood
99: 1517-1526
[Abstract][Full Text]
Quinn, E. R., Chan, C. H., Hadlock, K. G., Foung, S. K. H., Flint, M., Levy, S.
(2001). The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood
98: 3745-3749
[Abstract][Full Text]
Harig, S., Witzens, M., Krackhardt, A. M., Trojan, A., Barrett, P., Broderick, R., Zauls, A. J., Gribben, J. G.
(2001). Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood
98: 2999-3005
[Abstract][Full Text]
Schnurr, M., Galambos, P., Scholz, C., Then, F., Dauer, M., Endres, S., Eigler, A.
(2001). Tumor Cell Lysate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in Vitro Model for the Assessment of Tumor Vaccines. Cancer Res.
61: 6445-6450
[Abstract][Full Text]
Tolba, K. A., Bowers, W. J., Hilchey, S. P., Halterman, M. W., Howard, D. F., Giuliano, R. E., Federoff, H. J., Rosenblatt, J. D.
(2001). Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood
98: 287-295
[Abstract][Full Text]
Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., Engleman, E. G.
(2001). Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA
10.1073/pnas.141226398v1
[Abstract][Full Text]
Timmerman, J. M., Caspar, C. B., Lambert, S. L., Syrengelas, A. D., Levy, R.
(2001). Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood
97: 1370-1377
[Abstract][Full Text]
Rinaldi, M., Ria, F., Parrella, P., Signori, E., Serra, A., Ciafrè, S. A., Vespignani, I., Lazzari, M., Farace, M. G., Saglio, G., Fazio, V. M.
(2001). Antibodies Elicited by Naked DNA Vaccination against the Complementary-determining Region 3 Hypervariable Region of Immunoglobulin Heavy Chain Idiotypic Determinants of B-lymphoproliferative Disorders Specifically React with Patients' Tumor Cells. Cancer Res.
61: 1555-1562
[Abstract][Full Text]
Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., Timmerman, J.
(2001). Immunotherapy of Non-Hodgkin's Lymphomas. ASH Education Book
2001: 221-240
[Abstract][Full Text]
Huang, T.-H., Wu, P.-Y., Lee, C.-N., Huang, H.-I, Hsieh, S.-L., Kung, J., Tao, M.-H.
(2000). Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen. Blood
96: 3663-3670
[Abstract][Full Text]
Riemersma, S. A., Jordanova, E. S., Schop, R. F. J., Philippo, K., Looijenga, L. H. J., Schuuring, E., Kluin, P. M.
(2000). Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood
96: 3569-3577
[Abstract][Full Text]
Pulford, K., Falini, B., Banham, A. H., Codrington, D., Roberton, H., Hatton, C., Mason, D. Y.
(2000). Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood
96: 1605-1607
[Abstract][Full Text]
Borrello, I., Sotomayor, E. M., Rattis, F.-M., Cooke, S. K., Gu, L., Levitsky, H. I.
(2000). Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood
95: 3011-3019
[Abstract][Full Text]
Timmerman, J. M., Levy, R.
(2000). Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine. J. Immunol.
164: 4797-4803
[Abstract][Full Text]
Freedman, A. S., Neuberg, D., Mauch, P., Soiffer, R. J., Anderson, K. C., Fisher, D. C., Schlossman, R., Alyea, E. P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L. M., Gribben, J. G.
(1999). Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. Blood
94: 3325-3333
[Abstract][Full Text]
Levy, R.
(1999). Karnofsky Lecture: Immunotherapy of Lymphoma. JCO
17: 7-12
[Full Text]
Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B., Peola, S., Stiefel, T., Even, J., Novero, D., Boccadoro, M., Pileri, A.
(1999). Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood
94: 673-683
[Abstract][Full Text]
Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Goldstein, K. E., Engleman, E. G., Blume, K. G., Levy, R.
(1999). Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma---A Feasibility Study. Blood
93: 2411-2419
[Abstract][Full Text]
Shtil, A. A., Turner, J. G., Durfee, J., Dalton, W. S., Yu, H.
(1999). Cytokine-Based Tumor Cell Vaccine Is Equally Effective Against Parental and Isogenic Multidrug-Resistant Myeloma Cells: The Role of Cytotoxic T Lymphocytes. Blood
93: 1831-1837
[Abstract][Full Text]
Farrar, J. D., Katz, K. H., Windsor, J., Thrush, G., Scheuermann, R. H., Uhr, J. W., Street, N. E.
(1999). Cancer Dormancy. VII. A Regulatory Role for CD8+ T Cells and IFN-{gamma} in Establishing and Maintaining the Tumor-Dormant State. J. Immunol.
162: 2842-2849
[Abstract][Full Text]
Wong, C. P., Okada, C. Y., Levy, R.
(1999). TCR Vaccines Against T Cell Lymphoma: QS-21 and IL-12 Adjuvants Induce a Protective CD8+ T Cell Response. J. Immunol.
162: 2251-2258
[Abstract][Full Text]
McCormick, A. A., Kumagai, M. H., Hanley, K., Turpen, T. H., Hakim, I., Grill, L. K., Tuse, D., Levy, S., Levy, R.
(1999). Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl. Acad. Sci. USA
96: 703-708
[Abstract][Full Text]
Guillaume, T., Rubinstein, D. B., Symann, M.
(1998). Immune Reconstitution and Immunotherapy After Autologous Hematopoietic Stem Cell Transplantation. Blood
92: 1471-1490
[Full Text]
Davis, T. A., Maloney, D. G., Czerwinski, D. K., Liles, T.-M., Levy, R.
(1998). Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin's Lymphoma Without Eradicating the Malignant Clone. Blood
92: 1184-1190
[Abstract][Full Text]
Bagot, M., Echchakir, H., Mami-Chouaib, F., Delfau-Larue, M.-H., Charue, D., Bernheim, A., Chouaib, S., Boumsell, L., Bensussan, A.
(1998). Isolation of Tumor-Specific Cytotoxic CD4+ and CD4+CD8dim+ T-Cell Clones Infiltrating a Cutaneous T-Cell Lymphoma. Blood
91: 4331-4341
[Abstract][Full Text]
Kwak, L. W., Pennington, R., Boni, L., Ochoa, A. C., Robb, R. J., Popescu, M. C.
(1998). Cutting Edge: Liposomal Formulation of a Self Lymphoma Antigen Induces Potent Protective Antitumor Immunity. J. Immunol.
160: 3637-3641
[Abstract][Full Text]
Frickhofen, N., Muller, E., Sandherr, M., Binder, T., Bangerter, M., Wiest, C., Enz, M., Heimpel, H.
(1997). Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia. Blood
90: 4953-4960
[Abstract][Full Text]
Dorfman, D. M., Schultze, J. L., Shahsafaei, A., Michalak, S., Gribben, J. G., Freeman, G. J., Pinkus, G. S., Nadler, L. M.
(1997). In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation. Blood
90: 4297-4306
[Abstract][Full Text]
Caspar, C. B., Levy, S., Levy, R.
(1997). Idiotype Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formulations. Blood
90: 3699-3706
[Abstract][Full Text]
Cardoso, A. A., Seamon, M. J., Afonso, H. M., Ghia, P., Boussiotis, V. A., Freeman, G. J., Gribben, J. G., Sallan, S. E., Nadler, L. M.
(1997). Ex Vivo Generation of Human Anti-Pre-B Leukemia-Specific Autologous Cytolytic T Cells. Blood
90: 549-561
[Abstract][Full Text]
Vitetta, E. S., Tucker, T. F., Racila, E., Huang, Y.-W., Marches, R., Lane, N., Scheuermann, R. H., Street, N. E., Watanabe, T., Uhr, J. W.
(1997). Tumor Dormancy and Cell Signaling. V. Regrowth of the BCL1 Tumor After Dormancy Is Established. Blood
89: 4425-4436
[Abstract][Full Text]
Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M., Syrengelas, A., Taidi-Laskowski, B., Levy, R.
(1997). Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma --- Long-Term Results of a Clinical Trial. Blood
89: 3129-3135
[Abstract][Full Text]
Gidlof, C., Dohlsten, M., Lando, P., Kalland, T., Sundstrom, C., Totterman, T. H.
(1997). A Superantigen-Antibody Fusion Protein for T-Cell Immunotherapy of Human B-Lineage Malignancies. Blood
89: 2089-2097
[Abstract][Full Text]
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Garcia-Prats, M. D., DeLeo, A. B., Lotze, M. T.
(1997). Bone Marrow-Derived Dendritic Cells Serve as Potent Adjuvants for Peptide-Based Antitumor Vaccines. Stem Cells
15: 94-103
[Abstract][Full Text]
Lanzavecchia, A
(1993). Identifying strategies for immune intervention. Science
260: 937-944
[Abstract]
Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., Engleman, E. G.
(2001). Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA
98: 8809-8814
[Abstract][Full Text]
Previous
